ALK Positive and LUNGevity Foundation Announce Recipients of the 2022 ALK-Positive Research Awards

[NikoleV]

We are proud to announce the 2022 recipients of the ALK Positive/LUNGevity ALK-Positive Lung Cancer Research Awards. 
The grant monies, totaling $1.75 million, were raised by ALK Positive and represent patients with ALK-positive non-small cell lung cancer themselves directly influencing the direction and focus of the research that affects their lives. This year’s awardees are the third cohort to receive these awards.

The selected research projects will address unanswered questions in the ALK space and seek to quickly improve outcomes for the approximately 5% of patients with non-small cell lung cancer whose cancers have tested positive for an alteration in the anaplastic lymphoma kinase (ALK) gene.

The recipients of the 2022 ALK Positive/LUNGevity ALK-Positive Lung Cancer Research Awards are:   
Trever Bivona, MD, PhD, University of California, San Francisco—Defining and novel therapeutic targeting of ALK fusion protein granules
Roberto Chiarle, MD, Boston Children’s Hospital/Harvard Medical School—Development of ALK-specific TCR-T cells for the eradication of ALK+ NSCLC
Angel Qin, MD, University of Michigan—Gilteritinib for lorlatinib-resistant ALK NSCLC

"We are delighted to continue our partnership on translational and clinical trial research with LUNGevity Foundation. The three scientists selected for the 2022 ALK Positive/LUNGevity ALK-Positive Lung Cancer Research Awards are international experts in the field. Their projects will expand ALK Positive’s strategic investment in funding research that will add new treatment options to the current arsenal of tyrosine kinase inhibitor-based treatment regimens,” said Ken Culver, MD, Director of Research & Clinical Affairs of the ALK Positive patient-driven organization.

To learn more, visit https://bit.ly/3BeHMTN